Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
abrdn Life Sciences InvestorsHQL -2.47%51 PS Ratio is 3.61 as of Aug. 20, 2026, which is 40% below its 10-year median of 6.03. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,405 Asset Management companies, abrdn Life Sciences Investors ranks better than 72.74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, abrdn Life Sciences Investors's share price is $22.11.
abrdn Life Sciences Investors's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.13. Hence, abrdn Life Sciences Investors's PS Ratio for today is 3.61.
Warning Sign:
abrdn Life Sciences Investors stock PS Ratio (=8.05) is close to 1-year high of 8.05.
The historical rank and industry rank for abrdn Life Sciences Investors's PS Ratio or its related term are showing as below:
HQL'
s PS Ratio Range Over the Past 10 Years
Min: 3.25 Med: 6.03 Max: 18.71
Current: 3.62
During the past 9 years, abrdn Life Sciences Investors's highest PS Ratio was 18.71. The lowest was 3.25. And the median was 6.03.
HQL's PS Ratio is ranked better than 72.74% of 1405
companies
in the Asset Management industry
Industry Median: 7.16
vs HQL: 3.62
During the past 9 years, abrdn Life Sciences Investors's highest 3-Year average Revenue per Share Growth Rate was 28.40% per year. The lowest was -45.70% per year. And the median was 4.50% per year.
abrdn Life Sciences Investors (NYSE:HQL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
abrdn Life Sciences Investors PS Ratio Related Terms
abrdn Life Sciences Investors PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, abrdn Life Sciences Investors's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors PS Ratio vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's PS Ratio distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's PS Ratio falls into.
abrdn Life Sciences Investors PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
abrdn Life Sciences Investors's Share Price of today is $22.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.13.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
abrdn Life Sciences Investors (HQL) has a PS Ratio of 3.61 as of Aug. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on abrdn Life Sciences Investors and its competitors. This is 40% below median its historical median of 6.03. Over the past decade, abrdn Life Sciences Investors' PS Ratio has ranged from 3.25 to 18.71. According to the industry distribution chart, abrdn Life Sciences Investors ranks #383 out of 1405 companies in the Asset Management industry, placing it in the top 27.3%.
Is abrdn Life Sciences Investors' PS Ratio too high?
abrdn Life Sciences Investors' current PS Ratio of 3.61 is 40% below median its 10-year median of 6.03. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 18.71. The Asset Management industry median PS Ratio is 7.16. abrdn Life Sciences Investors' value of 3.61 is 49.6% below this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #383 out of 1405 companies in the Asset Management industry, which is above the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' PS Ratio compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #383 out of 1405 companies for PS Ratio. This puts abrdn Life Sciences Investors in the upper half of its industry. The industry median PS Ratio is 7.16. abrdn Life Sciences Investors' value of 3.61 is 49.6% below this benchmark. Historically, abrdn Life Sciences Investors' own PS Ratio has ranged from 3.25 to 18.71 over the past decade. While the company's 10-year median is 6.03 vs. the industry median of 7.16, abrdn Life Sciences Investors has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for an Asset Management company?
The median PS Ratio among Asset Management companies is 7.16, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current PS Ratio of 3.61 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median PS Ratio is 7.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current PS Ratio is 3.61, which is 40% below median its own 10-year median of 6.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current PS Ratio is 3.61, which is 40% below median its 10-year median of 6.03 and 49.6% below the Asset Management industry median of 7.16. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current PS Ratio is 3.61 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
PS Ratio: 3.61 (40% below median its 10-year median of 6.03)
GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
Industry Position: 49.6% below the Asset Management median (#383 of 1405)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
